Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the abuse potential of study drug lasmiditan.

Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth).

This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03286218
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 1
Start date September 15, 2017
Completion date November 20, 2017

See also
  Status Clinical Trial Phase
Completed NCT03648684 - Examining Expectancy Challenges to Prevent Nonmedical Prescription Stimulant Use N/A
Completed NCT03947749 - Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
Active, not recruiting NCT03129334 - Preventing Prescription Drug Abuse in Middle School Students N/A
Completed NCT04069403 - An Opioid Prescribing Nudge N/A
Completed NCT03612713 - Influence of Medication on Functional Connectivity Early Phase 1
Completed NCT03936985 - Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Recruiting NCT04885166 - Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention N/A
Completed NCT03165175 - Mobile Application for Prescription Drug-Abuse Education (MAPDE) N/A
Active, not recruiting NCT03219190 - A High School Program for Preventing Prescription Drug Abuse N/A